Nardone, V.; Patanè, V.; Marinelli, L.; D’Ambrosio, L.; Del Tufo, S.; De Chiara, M.; Brunese, M.C.; Rubini, D.; Grassi, R.; Russo, A.;
et al. Delta-Radiomics Biomarker in Colorectal Cancer Liver Metastases Treated with Cetuximab Plus Avelumab (CAVE Trial). Diagnostics 2025, 15, 2914.
https://doi.org/10.3390/diagnostics15222914
AMA Style
Nardone V, Patanè V, Marinelli L, D’Ambrosio L, Del Tufo S, De Chiara M, Brunese MC, Rubini D, Grassi R, Russo A,
et al. Delta-Radiomics Biomarker in Colorectal Cancer Liver Metastases Treated with Cetuximab Plus Avelumab (CAVE Trial). Diagnostics. 2025; 15(22):2914.
https://doi.org/10.3390/diagnostics15222914
Chicago/Turabian Style
Nardone, Valerio, Vittorio Patanè, Luca Marinelli, Luca D’Ambrosio, Sara Del Tufo, Marco De Chiara, Maria Chiara Brunese, Dino Rubini, Roberta Grassi, Anna Russo,
and et al. 2025. "Delta-Radiomics Biomarker in Colorectal Cancer Liver Metastases Treated with Cetuximab Plus Avelumab (CAVE Trial)" Diagnostics 15, no. 22: 2914.
https://doi.org/10.3390/diagnostics15222914
APA Style
Nardone, V., Patanè, V., Marinelli, L., D’Ambrosio, L., Del Tufo, S., De Chiara, M., Brunese, M. C., Rubini, D., Grassi, R., Russo, A., Belfiore, M. P., Ciardiello, F., Cappabianca, S., Martinelli, E., & Reginelli, A.
(2025). Delta-Radiomics Biomarker in Colorectal Cancer Liver Metastases Treated with Cetuximab Plus Avelumab (CAVE Trial). Diagnostics, 15(22), 2914.
https://doi.org/10.3390/diagnostics15222914
